Entrepreneurs are invited to the 429th FREE online 1Mby1M mentoring roundtable on Thursday, January 24, 2019, at 8 a.m. PST/11 a.m. EST/5 p.m. CET/9:30 p.m. India IST. If you are a serious entrepreneur, register to “pitch” and sell your business idea. You’ll receive straightforward feedback, advice on next steps, and answers to any of your questions. Others
Sramana Mitra: I’m just trying to understand the trends of this industry. If a technology provider is selling into the pharmaceutical industry in the digital therapeutics use case, how else is a digital therapeutics use case going to pan out commercially? Raj Agarwal: It’s early in the game. That’s a new trend. There are three
If you haven’t already, please study our Bootstrapping Course and Investor Introductions page. Over the last decade and more, I’ve had the privilege of working with a large number of bootstrapped entrepreneurs. These include self-financed companies and also modestly capitalized startups that operate in a capital-efficient manner applying the principles of bootstrapping. [You can review my Bootstrapping Course to
There aren’t many stories that one hears about Billion Dollar Unicorn players out of East European countries like Estonia. But ride-sharing service provider Taxify is one such rare gem. The company is already giving Uber tough competition in Europe.
As automation devastates the fundamental economic model of the human civilization, we are faced with the option of augmenting the human brain such that ALL unskilled, low-IQ humans become upgraded. I wrote on this topic last year: Man and Superman: Can Displaced Blue Collar Workers Become Doctors? Since then, Elon Musk has made public statements about
Sramana Mitra: You were basically selling license software at this point right? Keith Krach: Yes, we were selling license software. We said, “If we’re ever going to do this again, we’re going to pull as much expense as we can and push as much revenue out as we can. When it came to recognized revenue,
Sramana Mitra: Let’s switch the discussion to pharmaceuticals and where drugs are now being enhanced by various kinds of digital monitoring or reporting. What are the trends there? It seems like you have penetration in that use case as well. Raj Agarwal: One big trend on the pharma side is that they are recognizing that
In case you missed it, you can listen to the recording here: